

11 November 2009

**Address By Dato' Dr. Rajen
At Annual General Meeting of Holista collTech Limited**

A copy of the presentation made by Dato' Dr. Rajen, Managing Director of Holista CollTech Limited at today's Annual General Meeting of the Company is enclosed.



**A.H. Boys
Company Secretary
Holista CollTech Limited**

About Holista CollTech Limited

Holista CollTech Ltd is a merger of Holista Biotech Sdn Bhd and CollTech Australia Ltd focusing on natural ingredients for health supplements and lifestyle products. The company is the only producer of sheep (ovine) collagen using its patented extraction methods and is on track to develop a nano-encapsulated ovine collagen. Holista CollTech leads in research on herbs and food ingredients from Malaysia's rainforest – the oldest in the world. The company's mission is to build a world class company, focus on providing consumers with scientifically enhanced, engineered and tested natural health supplements and consumer products. The company is listed on the Australian Stock Exchange (HCT).

For personal use only

HOLISTA COLLTECH LIMITED

**Address by Dato' Dr. Rajen, Managing Director
at the AGM of Holista CollTech Limited 11 November 2009.**

The last 12 months have seen gut wrenching change both inside and outside the company. At the end of it, we are now a bigger and better company.

It started with us looking for a better source of collagen and it has ended up with a reverse take over.

I am happy to announce that we have emerged not only changed – in name and in form – but stronger and better to survive global turbulence. In the process we have repositioned ourselves from a fledging “biotech company” looking to raise funds to survive to a “wellness company” with sales, profits and several exciting technologies that will make a mark on the global marketplace.

Over the last 4 months since the corporate exercise, we have been busy. Among the things we achieved are:

- 1 in 10 stock consolidation
- Private placement of AUD3 million

With comfort of financial backing, we have made the following plays:

- Global distribution rights for several of our technologies
- Development of “food grade collagen” using an outsourced researcher, but funding it on our own without the need for grants that would tie us down to ongoing royalty payments.

The merger and acquisition in July 2009 has allowed the company to better finance its core business of ovine collagen but also allow us now to tap into Holista’s core businesses:

- Natural infection control
- High value natural ingredients
- Herbs of the Malaysian rainforests – the oldest in the world

As a prudent strategy, the original focus of “medical collagen” has been put on the backburner as we focused our time, money and energy on getting “food grade collagen” where the margins are smaller but the market is not only ready and waiting but also much bigger. This will give us the necessary profits and more important, the cash flows to support the “medical collagen” play in the longer term. This range of “food grade collagen” products will come on stream late in the first quarter of 2010. Indeed, our own subsidiary – ALTERNI – will switch from the current “halal” bovine to switch. Apart from that , we have waiting customers in China, Malaysia, Thailand and Indonesia where “food grade collagen” is hot but both bovine and porcine collagen present inherent problems.

Holista CollTech Limited ABN 24 094 515 992

PO Box 1661 Osborne Park WA 6916 Australia P +618 9426 3900 F +618 9426 3909

W www.colltech.com.au E sales@colltech.com.au

HOLISTA COLLTECH LIMITED

The markets are currently moving into marine food grade collagen for these reasons but we know very well that fish collagen is expensive, non-mammalian and non traceable.

We are also in discussion with one of India's major "halal" meat importer for a possibly Joint Venture or "licensing in" possibility. As you may know, India being secular with large Hindu, Muslim and Buddhist populations has issues with bovine and porcine collagen. Also, during the "mad cow disease" outbreak, a decision was taken to ban bovine collagen imports. Hence, India is a "starved" collagen market.

However, we are now working with Austrade to deliver not just collagen extraction technologies but a platform of Australian farming technologies namely farm management, milk production, abattoir management and animal blood product extraction. We believe that this would shift it from a "company agenda" to a "national agenda" that would work better and faster.

We have re-activated work on "nano collagen" with the University of Hamdard that is renowned in India for its nanotechnology laboratory. We have developed prototypes and plan being work on liposome encapsulation with a view to a patent in being filed at the end of the first quarter next year. The nano collagen is expected to hit the market in the second quarter of next year.

We are also seeking to re-activate our collagen eyedrop work with Hamdard who just filed the world's first nano turmeric eyedrop patent for glaucoma.

We made the announcement in August that our ovine collagen was involved in a US trial on tissue engineering in Ohio, funded by the government of the United States. We continue to track the progress. Full data will come in the first quarter of next year. This puts our company and ovine collagen in very exciting orbit of wound dressing and tissue engineering.

We are looking at a distribution arrangement into the United States for our collagen should the results of the BioAlliance LLC an Ohio based company

Let me take some time to discuss the possibilities with the natural infection control. These can be broadly classified into two:

- Mosquito control technologies
- Natural sanitizer (alcohol free)

Let us look at the mosquito control technologies. Here we have two core technologies;

- Controlling mosquitoes by controlling the larvae breeding naturally
- Repelling mosquitoes and other insects

The control of mosquito larvae is novel and we have a combination of natural bacteria crystals that kill larvae and a hormone that causes larvae starvation (called TMOF – Trypsin Modifying Oostatic factor), This combination is superior to existing bio-control methodologies in the following ways:

- Cheaper by a factor of 3-5 times
- Less application of once a month versus once a week
- Unlikeness of resistance developing (a big issue for mosquito control)

HOLISTA COLLTECH LIMITED

The technology is owned by Entogenex LLC, a company in North Carolina, USA. We have rights to all nations minus the United States for this technology. The technology is licensed from the University of Florida and has 16 patents around it. The product is approved by the United States Environmental Protection Agency (EPA).

Not surprisingly, there has been much interest from many governments in the tropical areas of the world, where mosquito borne diseases like dengue, malaria and chikunya kill many and infect many more.

We start a trial in Malaysia that is fully funded by the Malaysian Ministry of Health in the middle of November. Even more exciting, we are in the midst of discussion with the highest level of the Zambian government for a trial in the heart of Africa for malaria control. Malaria infects 300 million people and kills 3 million there each year.

That trial is being guided by Dr. Robert Rose who was with the EPA and Centre for Disease Control of the United States. He currently consults for the Bill & Melinda Gates Foundation. The outcome of the trial will be watched by

- ❖ **WHO** – World Health Organization
- ❖ **USAID** – United States Agency for International Development
- ❖ **CDC** – Centre for Disease Control, Atlanta
- ❖ **USDA** – United States Department of Agriculture
- ❖ The **Bill & Melinda Gates** Foundation
- ❖ **JICA** – Japan International Cooperation Agency

The other exciting technology is EGX101 – an active compound that is found in wild tomatoes. It has been found to be as effective as all the current toxic insect repellents that are mostly nerve toxins and are have deleterious effects on the environment.

The technology is owned by Entogenex LLC and much of the initial work was one in the University of Northern Carolina. Once again, we have rights for EGX 101 for the whole world except for the United States.

EGX 101 is completely safe to human, pets and the environment. It has also been registered by the Environmental Protection Agency (EPA) of the United States. Not surprisingly, it has been exempted from registration in by the Malaysian Pesticides Board and will likely get very similar treatment in much of the ASEAN nations where mosquitoes are really pests.

What is really exciting is that this compound will not be heavily regulated in the sales and marketing like its toxic alternatives. This will give an easier communication and education access to consumers by way of advertising and public relations. Branding and capturing markets for brands of EGX 101 will be easier, shorter and cheaper.

The other product in the infection control range is BluOxy. This unique combination is the world's first natural sanitizer that is totally alcohol free. It has been documented to kill a broad range of more than 100 pathogens including most recently, H1N1.

We continue to generate more data in Malaysia, Singapore, India, Australian, England and in the United States.

HOLISTA COLLTECH LIMITED

The formulation is proprietary but a global patent is being filed later this month.

As it is totally natural, it may be used in personal care. A nasal formulation is being developed with a patent filed soon.

The technology is owned by Kromos Biotechnology LLC, another company based in Northern Carolina, USA. We have global rights for this product in human applications.

We also have technologies that in the area of food ingredients namely:

- Reduction of glycemic index
- Reduction of “fat pulled into” potato fries
- A low sodium salt

All these are being tested and validated by the Nutrition and Food Research Group at Oxford Brookes, is internationally renowned for its work on Glycaemic Index and is the largest Testing Centre in Europe.

A very large multinational fast food chain has shown interest in this and is also keen to pursue in house testing. They have asked for one year exclusivity on the technologies. We have agreed.

We continue to work on our herbs of the rainforest. We continue work at the ground breaking work with the Indian Institute of Integrative Medicine, University of Hamdard, New Delhi and the National Center for Natural Products Research at the University of Mississippi.

We are now in the midst of giving the global distribution rights to a Malaysian company focused in Malay herbs. This would allow the development of this range in the Malaysia, the region and the Middle East.

Meanwhile, we continue to improve and strengthen Holista’s trading and product development operations at in Malaysia and the region.

Now, you will understand why I started by saying that the company has made some major changes that will put in on the path of growth. There is a lot of opportunity but there is a lot that needs to be done and some major challenges to face.

I wish to take a moment to thank Steven Carter for making this happen. He was instrumental in the reverse takeover process. Indeed, he made the deal happen. As with everything else, he wants to move on to greater and bigger things.

Please join me in thanking Steven Carter and wishing him all the best in his future undertakings.

Once again, I thank all of you for your support of the companies and the patience that you have shown.

****Ends****